slides · global inventory
53 Jobs To Be Done
Loop collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 1,583
Current window 1,021-1,050
Pages 53
Rows per page 30
Loop
1,021-1,050 of 1,583
06
The diagram uses a Venn-like overlap to visually represent the expansion of 'right sequences' explored.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · AgitateLoop · Jobs To Be Done1 hit
07
The slide uses a flywheel/cycle diagram to represent the iterative nature of their platform.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
08
The central circular diagram represents a flywheel or iterative process.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
09
The slide uses a process flow diagram to explain the drug discovery pipeline from patient cohort to manufacturing.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
10
The slide uses a process flow diagram to illustrate the transformation of biological targets into optimized drug candidates.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
11
The slide uses a process-flow visual to contrast discovery vs. optimization.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
12
The slide features the company logo and a stylized 'a' graphic.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
13
The slide highlights a specific Nature Biomedical Engineering paper as validation of the company's core technology approach.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
14
The slide uses a process flow diagram to show the transition from parental mAb to optimized mAb via AI.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
15
The slide outlines a technical methodology for biological data generation.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
16
The slide includes a small schematic icon representing the scatter plot and a callout box emphasizing the necessity of high-quality data for AI training.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
17
The table outlines the experimental design for antibody optimization models, specifically highlighting the differences in sampling strategies and mutational loads.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
18
The slide explains the methodology behind the dataset used for AI lead optimization, specifically focusing on the combinatorial space of amino acid mutations.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
19
Includes scatter plots showing correlation and a bar chart comparing model performance metrics against experimental replicates.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
20
The chart shows density vs -log10Kd, comparing design vs validation vs measured trastuzumab.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
21
The slide highlights the methodology of sampling sequence space and validating predictive models against measured binding affinity.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
22
The chart compares High vs Low Fidelity models with and without pretraining across different training data sizes.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
23
The slide shows scatter plots for quadruple and quintuple mutants and a summary bar chart for performance metrics.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
24
The slide uses a combination of diagrams and a summary box to explain the methodology of using AI to predict antibody naturalness.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
25
The slide uses box plots and bar charts to show statistical correlation between naturalness and clinical/developability outcomes.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
26
The slide uses box plots and density plots to demonstrate that higher naturalness correlates with better expression and lower mutational burden.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
10
Includes longitudinal CT scan imagery and a line chart tracking tumor diameter and volume reduction.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
11
Waterfall plot shows individual patient responses; ORR, PFS, and OS metrics provided.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
12
The slide uses a central human anatomy diagram to map specific cancer types to their respective mesothelin expression rates.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
13
The slide uses a vertical process flow to link four strategic modifications to two distinct patient groups (Ovarian/Mesothelioma and NSCLC/Cholangiocarcinoma).TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
14
TCR2 Therapeutics | Results Presentation Deck | 34 slidesTCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
15
The slide uses a process diagram to illustrate the dose escalation cohorts leading to the Recommended Phase 2 Dose (RP2D).TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
16
RP2D (Recommended Phase 2 Dose) is highlighted at DL 3.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
17
The table categorizes adverse events into Hematologic, On Target/On Tumor, On Target/Off Tumor, and Other, with a specific highlight on the RP2D (Recommended Phase 2 Dose) column.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
18
Waterfall plot is a standard clinical trial visualization for tumor response.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit